Novakand Pharma AB (FRA:3EE0) Cyclically Adjusted PB Ratio: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Novakand Pharma AB Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Novakand Pharma AB  (FRA:3EE0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novakand Pharma AB Cyclically Adjusted PB Ratio Related Terms


Novakand Pharma AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Novakand Pharma AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novakand Pharma AB Cyclically Adjusted PB Ratio Chart

Novakand Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.28 0.95 2.09 0.56 0.09

Novakand Pharma AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.58 0.98 0.15 0.09

FRA:3EE0 vs VRTX, REGN, ALNY: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Novakand Pharma AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novakand Pharma AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novakand Pharma AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novakand Pharma AB's Cyclically Adjusted PB Ratio falls into.



Novakand Pharma AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novakand Pharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 is calculated as:

For example, Novakand Pharma AB's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book=Book Value per Share/CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.011/133.3900*133.3900
=0.011

Current CPI (Dec. 2025) = 133.3900.

Novakand Pharma AB Quarterly Data

Book Value per Share CPI Adj_Book
201603 0.116 100.751 0.154
201606 0.408 101.019 0.539
201609 0.368 101.138 0.485
201612 0.328 102.022 0.429
201703 0.281 102.022 0.367
201706 0.307 102.752 0.399
201709 0.233 103.279 0.301
201712 0.191 103.793 0.245
201803 0.126 103.962 0.162
201806 0.225 104.875 0.286
201809 0.177 105.679 0.223
201812 0.132 105.912 0.166
201903 0.098 105.886 0.123
201906 0.071 106.742 0.089
201909 0.084 107.214 0.105
201912 0.061 107.766 0.076
202003 0.000 106.563 0.000
202006 0.139 107.498 0.172
202009 0.154 107.635 0.191
202012 0.124 108.296 0.153
202103 0.113 108.360 0.139
202106 0.213 108.928 0.261
202109 0.196 110.338 0.237
202112 0.178 112.486 0.211
202203 0.156 114.825 0.181
202206 0.133 118.384 0.150
202209 0.116 122.296 0.127
202212 0.119 126.365 0.126
202303 0.098 127.042 0.103
202306 0.079 129.407 0.081
202309 0.067 130.224 0.069
202312 0.051 131.912 0.052
202403 0.068 132.205 0.069
202406 0.061 132.716 0.061
202409 0.052 132.304 0.052
202412 0.045 132.987 0.045
202503 0.037 132.825 0.037
202506 0.032 133.699 0.032
202509 0.015 133.480 0.015
202512 0.011 133.390 0.011

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novakand Pharma AB Business Description

Address Nanna Svarts vag 4, Solna, SWE, 171 65
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.